AlphAIAlphAI — Financial news for AI agents
investing.comOCT 292 min read$ALNY

Stifel downgrades Alnylam stock rating on Amvuttra concerns

Stifel downgraded Alnylam Pharmaceuticals (ALNY) to Hold from Buy, lowering its price target to $225 from $318. The firm cited concerns about Amvuttra's near-term performance and market challenges. Despite a strong Q3 2026 earnings beat, ALNY's stock fell due to guidance concerns and slower TTR franchise growth. The stock is near its 52-week low of $197.81, with a 79.7% gross profit margin.

Original reporting
investing.com
Published Oct 29, 2026, 3:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 3:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$ALNY
Bearish
high confidence
Mentioned
$ALNY
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ALNYBearishMed
01

Why it matters

The downgrade reflects analyst skepticism on near‑term revenue from the TTR franchise despite solid earnings.

02

Market read

The downgrade adds fresh negative sentiment to ALNY, potentially prompting short‑term sell pressure.

03

What to watch

Potential upside from upcoming TRITON‑CM trial success and pipeline programs.

Relevance 7/10Novelty 7/10Timing: today

Background

Alnylam reported strong Q3 earnings but shares fell amid concerns over Amvuttra commercialization and guidance.

Company-level read

Ticker impact

$ALNYBearishHigh confidence
Context

Stifel downgraded Alnylam Pharmaceuticals (ALNY) to Hold and cut its price target to $225 from $318.

Expected impact

likely downward pressure as investors price in the downgrade and reduced target

Evidence & confidence

Stifel cited declining Amvuttra numbers and commercial headwinds, making the stock harder to justify a buy rating.

Market effects

Sector

The downgrade may weigh on other TTR‑focused biotech stocks.

Regional

Limited to U.S. biotech sector.

Global

Minimal global impact beyond the niche gene‑silencing market.

Counterpoint

What could challenge this read

If Amvuttra's long‑term potential materializes, the downgrade could be premature.

Key entities

  • company
    Alnylam Pharmaceuticals

    Biotech firm developing RNAi therapeutics.

  • analyst
    Stifel

    Equity research firm issuing the downgrade.

Read at source← All news

Related articles

OCT 29
$ALNYMed

Alnylam Pharmaceuticals Q3 Earnings Call Highlights

Alnylam Pharmaceuticals reported that AMVUTTRA has access for 99% of covered lives, with 90% of patients within 10 miles of treatment. The company is monitoring a proposed CMS rule that could reduce Medicare reimbursement for 340B drugs, which represents a meaningful portion of its business. UnitedHealth implemented a restrictive policy for AMVUTTRA, potentially delaying access for new patients.

finance.yahoo.com2 min
OCT 29
$ALNYHighAI 8/10

Alnylam (ALNY) Q3 2026 Earnings Call Transcript

Alnylam (ALNY) reported Q3 2026 revenue of $1.46B, up 17% YoY, driven by TTR franchise growth. AMVUTTRA sales rose 65% YoY to $1.13B. Guidance for TTR product sales was lowered to the range of $4.2B-$4.5B. Management cited Medicare Advantage policy changes and 340B reimbursement adjustments as risks. TRITON-CM study enrollment target was expanded to 2,250 patients.

fool.com3 min
OCT 29
$ALNYMed

Alnylam Sinks 19% as It Expands Nucresiran Heart Trial Again, Citing “A High Level of Conviction”

Alnylam Pharmaceuticals (ALNY) shares fell 19% after expanding its nucresiran heart trial to 2,250 patients, citing confidence in positive results. Despite 52% product revenue growth, concerns arise about nucresiran's benefit. Analysts expect revenue growth through 2028, driven by AMVUTTRA. Competitors like Pfizer (PFE) and BridgeBio (BBIO) may gain if nucresiran's data is weak.

finance.yahoo.com2 min
OCT 29
$ALNYHighAI 8/10

Alnylam Reports 17% Q3 Revenue Growth, Expands Nucresiran Trial And Advances RNAi Pipeline

Alnylam Pharmaceuticals (ALNY) reported Q3 2026 revenue growth of 16.7% to $1.458 billion, driven by a 52% increase in global net product revenue, primarily from its TTR franchise. Net income rose to $2.167 billion. The company expanded its Phase 3 study for nucresiran and presented promising early data for brezosiran in Huntington's disease. Alnylam also advanced its pipeline with mivelsiran and ALN-5288 for neurological diseases.

rttnews.com3 min